The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer

被引：0

作者：

DeCaire, Ximena ^{[1
]}

Streu, Erin ^{[1
]}

机构：

[1] CancerCare Manitoba, Winnipeg, MB, Canada

来源：

ONCOLOGY NURSING FORUM | 2016年 / 43卷 / 05期

关键词：

ambulatory care/office nursing; biotherapy/targeted therapies; clinical practice; lung cancer; CRIZOTINIB; ADENOCARCINOMA; FUSIONS;

D O I：

10.1188/16.ONF.544-547

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the advent of targeted therapy and changed the clinical landscape. ROS1 is a rare driver mutation found in 1%-2% of patients diagnosed with NSCLC. This case highlights a young woman of Asian descent with no history of smoking diagnosed with NSCLC and ROS1 rearrangement and discusses the implications for oncology nurses in clinical practice.

引用

页码：544 / 547

页数：4

共 50 条

[31] Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis
Soussi, G.
Hercent, A.
Gounant, V.
Lupo, A.
Cazes, A.
Lamoril, J.
Guyard, A.
Theou-Anton, N.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S489 - S489
[32] ALK rearrangement in non-small cell lung cancer
Naulleau, Gaspard
Birsen, Gary
Mansuet-Lupo, Audrey
Leroy, Karen
Wislez, Marie
BULLETIN DU CANCER, 2025, 112 (03) : 3S86 - 3S94
[33] Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Li, Ziming
Shen, Lan
Ding, Ding
Huang, Jia
Zhang, Jie
Chen, Zhiwei
Lu, Shun
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 987 - 995
[34] ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases
Warth, Arne
Muley, Thomas
Dienemann, Hendrik
Goeppert, Benjamin
Stenzinger, Albrecht
Schnabel, Philipp A.
Schirmacher, Peter
Penzel, Roland
Weichert, Wilko
HISTOPATHOLOGY, 2014, 65 (02) : 187 - 194
[35] Validating ROS1 Rearrangements As a Therapeutic Target in Non-Small-Cell Lung Cancer
Solomon, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 972 - 974
[36] Taletrectinib adipate Dual ROS1 and NTRK inhibitor Treatment of non-small cell lung cancer Treatment of solid tumors
Zhang, Zifan
Gao, Congying
Ma, Xiangyu
Li, Zheshen
Ashby, Charles R., Jr.
Wei, Liuya
Chen, Zhe-Sheng
DRUGS OF THE FUTURE, 2022, 47 (07) : 489 - 499
[37] Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells
Luo, Lian-Xiang
Fan, Xing-Xing
Li, Ying
Peng, Xia
Ji, Yin-Chun
Hsiao, Wendy Wen-Luan
Liu, Liang
Leung, Elaine Lai-Han
Yao, Xiao-Jun
MEDCHEMCOMM, 2017, 8 (03) : 621 - 624
[38] ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy
Lukas, Rimas V.
Hasan, Yasmin
Nicholas, Martin K.
Salgia, Ravi
JOURNAL OF CLINICAL NEUROSCIENCE, 2015, 22 (12) : 1978 - 1979
[39] KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
Eklund, Ella A.
Wiel, Clotilde
Fagman, Henrik
Akyurek, Levent M.
Raghavan, Sukanya
Nyman, Jan
Hallqvist, Andreas
Sayin, Volkan, I
CANCERS, 2022, 14 (09)
[40] Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer
Pavlakis, Nick
Cooper, Caroline
John, Thomas
Kao, Steven
Klebe, Sonja
Lee, Chee Khoon
Leong, Trishe
Millward, Michael
O'Byrne, Ken
Russell, Prudence A.
Solomon, Benjamin
Cooper, Wendy A.
Fox, Stephen
PATHOLOGY, 2019, 51 (07) : 673 - 680

← 1 2 3 4 5 →